Terns Pharmaceuticals logo
Terns Pharmaceuticals TERN
$ 5.73 2.23%

Quarterly report 2024-Q3
added 11-12-2024

report update icon

Terns Pharmaceuticals Balance Sheet 2011-2024 | TERN

Annual Balance Sheet Terns Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-142 M - -62 M -12.3 M -82.5 M - - - - - - -

Long Term Debt

- 544 K - - - - - - - - - - -

Long Term Debt Current

603 K 661 K - - - - - - - - - - -

Total Non Current Liabilities

- - - 877 K 14.7 M 14.5 M - - - - - - -

Total Current Liabilities

11.9 M 8.47 M 6.82 M - - - - - - - - - -

Total Liabilities

13.2 M 10.1 M 7.77 M 23.7 M 19.7 M 16.8 M - - - - - - -

Deferred Revenue

- - - 836 K - - - - - - - - -

Retained Earnings

-333 M -242 M -182 M -132 M -91.9 M -23.3 M - - - - - - -

Total Assets

269 M 287 M 168 M 92.3 M 23.9 M 89.1 M - - - - - - -

Cash and Cash Equivalents

79.9 M 143 M 47.7 M - - - - - - - - - -

Book Value

255 M 277 M 160 M 68.6 M 4.21 M 72.2 M - - - - - - -

Total Shareholders Equity

255 M 277 M 160 M -117 M - - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Terns Pharmaceuticals

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

1.03 M - - - 63 K 223 K 386 K 544 K 702 K 851 K 1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

13.8 M 12.2 M 10 M 13.2 M 13.3 M 15.5 M 13.6 M 10.1 M 8.89 M 7.64 M 7.95 M 7.77 M 7.73 M 6.68 M 9.24 M 23.7 M 23.7 M 23.7 M 23.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-400 M -378 M -355 M -333 M -312 M -282 M -264 M -242 M -227 M -210 M -196 M -182 M -168 M -156 M -145 M -132 M -132 M -132 M -132 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

378 M 231 M 247 M 269 M 272 M 290 M 301 M 287 M 193 M 145 M 157 M 168 M 180 M 188 M 199 M 92.3 M 92.3 M 92.3 M 92.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

270 M 91.5 M 65.1 M 79.9 M 37.9 M 80.9 M 184 M 143 M 63 M 16.8 M 43.9 M 47.7 M 64.8 M 67.6 M 98.8 M 74.9 M 74.9 M 74.9 M 74.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

364 M 219 M 237 M 255 M 258 M 274 M 288 M 277 M 184 M 137 M 149 M 160 M 172 M 181 M 190 M 68.6 M 68.6 M 68.6 M 68.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

364 M 219 M 237 M 255 M 258 M 274 M 288 M 277 M 184 M 137 M 149 M 160 M 172 M 181 M 190 M -117 M -117 M -117 M -117 M -90.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency